Norian begins tibial plateau fracture trial
This article was originally published in Clinica
Norian has begun a multi-centre trial in Europe of its SRS skeletal repair system for the treatment of tibial plateau fractures. The company has started enrolling patients at three European sites and plans to expand an additional five sites over the next few months. It believes that its injectable cancellous bone fixation material will provide direct structural support to the articular surface, improve fixation of screws and reduce the amount of hardware required.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.